Prior Authorization Request Form for guselkumab (Tremfya)



JOHNS HOPKINS **HEALTHCARE**

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

Step

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider		
Drug Name:	Strength:	
Dosage/Frequency (SIG):	Duration of Therapy:	

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step	Please complete patient and physician information	(please print):			
1	Patient Name:	Physician Name:			
-	Address: Address:				
	Sponsor ID #	Phone #:			
	Date of Birth:	Secure Fax #:			
Step 2	Please complete the clinical assessment:				
	Humira is the Department of Defense's preferred targeted biologic agent. Has the patient tried Humira?	?	□ No		
		proceed to question 2	proceed to question 4		
	Has the patient had an inadequate response to Humira?	□ Yes	□ No		
		proceed to question 5	proceed to question 3		
	3. Has the patient experienced an adverse reaction to Humira that is not expected to occur with the requested agent?	□ Yes	□ No		
		proceed to question 5	STOP		
			Coverage not approved		
	4. Does the patient have a contraindication to Humira (adalimumab)?	□ Yes	□ No		
	(aaaimamas).	proceed to question 5	STOP		
			Coverage not approved		
	5. Has the patient tried and experienced an inadequate response, had an adverse reaction, or have a	□ Yes	□ No		
	contraindication to Cosentyx (secukinumab)?	proceed to question 6	STOP		
			Coverage not approved		
	6. Has the patient tried and experienced an inadequate response, had an adverse reaction, or have a	□ Yes	□ No		
	contraindication to Stelara (ustekinumab)?	proceed to question 7	STOP		
			Coverage not approved		

Continue on next page

guselkumab (Tremfya) Page 2

	7. Is the patient 18 years of age or older?	□ Yes	□ No
		proceed to question 8	STOP
	8. Does this adult patient have a diagnosis of moderate to severe plaque psoriasis who is a candidate for phototherapy or systemic therapy? 9. Has the patient had an inadequate response to non-biologic systemic therapy? (For example: methotrexate, aminosalicylates [e.g. sulfasalazine, mesalamine], corticosteroids, immunosuppressants [e.g. azathioprine], etc.)		Coverage not approved
		□ Yes	□ No
		proceed to question 9	STOP
			Coverage not approved
		□ Yes	□ No
		proceed to question 10	STOP
			Coverage not approved
	10. Does the patient have evidence of a negative TB test	□ Yes	□ No
	result in the past 12 months (or TB is adequately managed)?	proceed to question 11	STOP
			Coverage not approved
	11. Will the patient be receiving other targeted immunomodulatory biologics with the requested		
	medication, including but not limited to the following:	□ Yes	□ No
	Actemra, Cimzia, Cosentyx, Enbrel, Humira, Ilumya, Kevzara, Kineret, Olumiant, Orencia, Otezla, Remicade,	STOP	Sign and date below
	Rituxan, Siliq, Simponi, Stelara, Taltz, or Xeljanz/Xeljanz XR?	Coverage not approved	
Step 3	I certify the above is true to the best of my knowled	lge. Please sign and da	te:
	Prescriber Signature	 Date	
	Prescriber Signature	Date	[29 May 2019]
	Prescriber Signature	Date	[29 May 2019]
or Inte	Prescriber Signature ernal Use Only	Date	[29 May 2019]
	•	Date Duration of Approval:	
	ernal Use Only roved:		
☐ Appr ☐ Deni	ernal Use Only roved:	Duration of Approval:	